Quick News Bit

Two Depression Drugs Flop; ECT vs Ketamine; ‘Depressive Realism’ Squashed

0

The investigational drug REL-1017 flopped for patients with major depressive disorder in the phase III RELIANCE III trial, failing to make a significant dent in depression symptoms by day 28, Relmada Therapeutics announced.

In other news, Arrivo BioVentures’ major depressive disorder treatment candidate SP-624 — a potential first-in-class sirtuin 6 activator — also missed its primary endpoint in a phase II study, failing to improve symptom scores in all study participants. However, in a post-hoc analysis, women saw a significant improvement at week 4 of treatment.

Meanwhile, zuranolone 50 mg significantly improved depressive symptoms by day 15, with benefits seen as early as day 3, among adult women with postpartum depression. Developers Sage Therapeutics and Biogen presented the phase III SKYLARK study findings at the 35th European College of Neuropsychopharmacology Congress.

Could the addiction drug naltrexone (Vivitrol) actually be a promising treatment for long COVID symptoms like brain fog? (Reuters)

In a systematic review and meta-analysis of six trials, electroconvulsive therapy (ECT) was a bit more effective for depressive symptoms compared with ketamine. “Treatment options should be individualized and patient-centered, considering different adverse effect profiles and patient preferences,” the researchers wrote in JAMA Psychiatry.

Getting an attention deficit-hyperactivity disorder (ADHD) diagnosis in childhood didn’t appear to improve quality of life in adolescence and was linked with a greater risk of self-harm when compared to adolescents with similar levels of hyperactive/inattentive behaviors who had never received a formal ADHD diagnosis. (JAMA Network Open)

Researchers are dismissing the theory of “depressive realism,” which suggests that people with depression simply see the world more realistically. (Collabra: Psychology)

The FDA rejected Minerva Neurosciences’ new drug application for roluperidone — for the treatment of negative symptoms in schizophrenia — hitting the developer with a refusal to file letter.

  • author['full_name']

    Kristen Monaco is a staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.

For all the latest Health News Click Here 

 For the latest news and updates, follow us on Google News

Read original article here

Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.

Leave a comment